Literature DB >> 20418476

Alterations in membrane type-1 matrix metalloproteinase abundance after the induction of thoracic aortic aneurysm in a murine model.

Jeffrey A Jones1, Jean Marie Ruddy, Shenikqua Bouges, Juozas A Zavadzkas, Theresa A Brinsa, Robert E Stroud, Rupak Mukherjee, Francis G Spinale, John S Ikonomidis.   

Abstract

Thoracic aortic aneurysms (TAAs) develop as a result of dysregulated extracellular matrix remodeling mediated by several matrix metalloproteinases (MMPs). Membrane type-1 MMP (MT1-MMP) is the prototypical member of a unique family of membrane-bound MMPs, possessing multiple substrates and functions. The present study tested the hypothesis that MT1-MMP expression, abundance, and activity would be elevated during TAA development and that this protease is produced primarily by mesenchymal cells within the thoracic aorta. Descending thoracic aortas were harvested from C57BL/6J mice at multiple time points (2, 4, 8, and 16 wk, n = 15 each) post-TAA induction (0.5M CaCl(2), 15 min) and compared with reference controls (n = 15). The expression and abundance of MT1-MMP, MMP-2, and tissue inhibitor of metalloproteinase (TIMP)-2 were assessed by quantitative PCR and immunoblot analysis. MT1-MMP activity was determined by fluorescent peptide assay. MT1-MMP was localized within the aortic wall by immunohistochemistry. MT1-MMP abundance and localization in live animals (8 wk post-TAA induction vs. control) was determined by micro-ultrasound imaging with an MT1-MMP-targeted microbubble contrast agent. Aortic diameter was increased 172 +/- 7% at 16 wk post-TAA induction (P < 0.05). MT1-MMP and MMP-2 mRNA levels were elevated at 2 wk post-TAA induction (P < 0.05). MT1-MMP protein abundance increased progressively to a maximum of 178 +/- 26% at 16 wk post-TAA induction, whereas MMP-2 and TIMP-2 peaked at 2 wk post-TAA induction (526 +/- 93% and 376 +/- 48%, respectively, P < 0.05). MT1-MMP colocalized with fibroblasts, and MT1-MMP-targeted contrast binding was elevated in 8-wk TAA-induced mice versus control mice (217 +/- 53% vs. 81 +/- 8%, P < 0.05). In conclusion, these novel results suggest that MT1-MMP plays a dynamic multifunctional role in TAA development and, therefore, may provide a significant target for therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20418476      PMCID: PMC2904124          DOI: 10.1152/ajpheart.00028.2010

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  41 in total

1.  Cellular activation of proMMP-13 by MT1-MMP depends on the C-terminal domain of MMP-13.

Authors:  Vera Knäuper; Louise Bailey; Joanna R Worley; Paul Soloway; Margaret L Patterson; Gillian Murphy
Journal:  FEBS Lett       Date:  2002-12-04       Impact factor: 4.124

2.  Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2.

Authors:  K Imai; E Ohuchi; T Aoki; H Nomura; Y Fujii; H Sato; M Seiki; Y Okada
Journal:  Cancer Res       Date:  1996-06-15       Impact factor: 12.701

3.  Organization of fibroblasts in the heart.

Authors:  Edie C Goldsmith; Adam Hoffman; Mary O Morales; Jay D Potts; Robert L Price; Alex McFadden; Michael Rice; Thomas K Borg
Journal:  Dev Dyn       Date:  2004-08       Impact factor: 3.780

4.  Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface.

Authors:  Albert Remacle; Gillian Murphy; Christian Roghi
Journal:  J Cell Sci       Date:  2003-08-12       Impact factor: 5.285

5.  Relation between ventricular and myocyte remodeling with the development and regression of supraventricular tachycardia-induced cardiomyopathy.

Authors:  F G Spinale; J L Zellner; M Tomita; F A Crawford; M R Zile
Journal:  Circ Res       Date:  1991-10       Impact factor: 17.367

6.  Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks.

Authors:  John A Elefteriades
Journal:  Ann Thorac Surg       Date:  2002-11       Impact factor: 4.330

7.  A murine model of thoracic aortic aneurysms.

Authors:  John S Ikonomidis; William C Gibson; Jonathan Gardner; Sarah Sweterlitsch; Robert P Thompson; Rupak Mukherjee; Francis G Spinale
Journal:  J Surg Res       Date:  2003-11       Impact factor: 2.192

8.  Thoracic aortic aneurysms: a population-based study.

Authors:  L K Bickerstaff; P C Pairolero; L H Hollier; L J Melton; H J Van Peenen; K J Cherry; J W Joyce; J T Lie
Journal:  Surgery       Date:  1982-12       Impact factor: 3.982

9.  Early MT-1 MMP expression following elastase exposure is associated with increased cleaved MMP-2 activity in experimental rodent aortic aneurysms.

Authors:  Indranil Sinha; Kevin K Hannawa; Jonathan L Eliason; Gorav Ailawadi; Michael P Deogracias; Siddharth Bethi; John W Ford; Karen J Roelofs; Vladimir Grigoryants; Peter K Henke; James C Stanley; Gilbert R Upchurch
Journal:  Surgery       Date:  2004-08       Impact factor: 3.982

10.  Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm.

Authors:  T Freestone; R J Turner; A Coady; D J Higman; R M Greenhalgh; J T Powell
Journal:  Arterioscler Thromb Vasc Biol       Date:  1995-08       Impact factor: 8.311

View more
  15 in total

Review 1.  Matrix metalloproteinases and descending aortic aneurysms: parity, disparity, and switch.

Authors:  Tom P Theruvath; Jeffrey A Jones; John S Ikonomidis
Journal:  J Card Surg       Date:  2011-09-29       Impact factor: 1.620

Review 2.  Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease.

Authors:  Mina M Benjamin; Raouf A Khalil
Journal:  Exp Suppl       Date:  2012

3.  Pressure overload-dependent membrane type 1-matrix metalloproteinase induction: relationship to LV remodeling and fibrosis.

Authors:  Michael R Zile; Catalin F Baicu; Robert E Stroud; An Van Laer; Jazmine Arroyo; Rupak Mukherjee; Jeffrey A Jones; Francis G Spinale
Journal:  Am J Physiol Heart Circ Physiol       Date:  2012-01-27       Impact factor: 4.733

Review 4.  Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.

Authors:  Xi Wang; Raouf A Khalil
Journal:  Adv Pharmacol       Date:  2017-09-19

5.  Selective microRNA suppression in human thoracic aneurysms: relationship of miR-29a to aortic size and proteolytic induction.

Authors:  Jeffrey A Jones; Robert E Stroud; Elizabeth C O'Quinn; Laurel E Black; Jeremy L Barth; John A Elefteriades; Joseph E Bavaria; Joseph H Gorman; Robert C Gorman; Francis G Spinale; John S Ikonomidis
Journal:  Circ Cardiovasc Genet       Date:  2011-10-18

Review 6.  Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders.

Authors:  Jie Liu; Raouf A Khalil
Journal:  Prog Mol Biol Transl Sci       Date:  2017-05-10       Impact factor: 3.622

7.  Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms.

Authors:  John S Ikonomidis; Elizabeth K Nadeau; Adam W Akerman; Robert E Stroud; Rupak Mukherjee; Jeffrey A Jones
Journal:  J Thorac Cardiovasc Surg       Date:  2016-11-14       Impact factor: 5.209

Review 8.  Molecular pathogenesis of genetic and sporadic aortic aneurysms and dissections.

Authors:  Ying H Shen; Scott A LeMaire
Journal:  Curr Probl Surg       Date:  2017-02-03       Impact factor: 1.909

9.  Ascending Aortic Proaneurysmal Genetic Mutations with Antiatherogenic Effects.

Authors:  Alexander Curtis; Tanya Smith; Bulat A Ziganshin; John A Elefteriades
Journal:  Int J Angiol       Date:  2015-08-17

10.  Reproducible porcine model of thoracic aortic aneurysm.

Authors:  Shaina R Eckhouse; Christina B Logdon; J Marshall Oelsen; Risha K Patel; Allison D Rice; Robert E Stroud; W Benjamin Wince; Rupak Mukherjee; Francis G Spinale; John S Ikonomidis; Jeffrey A Jones
Journal:  Circulation       Date:  2013-09-10       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.